PV Reporter, in partnership with Sanguine Biosciences, is reaching out to raise awareness about an at-home research opportunity for patients diagnosed with Myelofibrosis. What is the goal of the at-home research? The goal of this research is to enhance their understanding of Myelofibrosis, in support of developing new diagnostic and treatment options for patients living […]
Chet Lemon Dies from PV Complications at 70
Chet Lemon, a beloved former Major League Baseball outfielder and 1984 World Series winner, died at the age of 70. Lemon passed on Thursday, May 8, 2025, after a decades-long battle with polycythemia vera (PV), a rare blood disorder, and its associated complications. Lemon, a three-time All-Star, was diagnosed with polycythemia vera in 1990, toward […]
FDA Grants Fast Track to Givinostat for Polycythemia Vera
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to givinostat, an oral histone deacetylase inhibitor (HDACi) developed by Italfarmaco S.p.A., for the treatment of polycythemia vera (PV), a rare hematologic malignancy. This designation aims to expedite the development and review of drugs that address serious conditions with unmet medical needs. PV […]
Gut Microbiome and Polycythemia Vera: What You Should Know
by David Wallace Recent research has uncovered significant differences in the gut microbiota of individuals with polycythemia vera (PV) compared to healthy individuals. Polycythemia vera, an uncommon blood cancer classified as a myeloproliferative neoplasm (MPN), causes abnormal blood cell growth and is characterized by chronic inflammation. The Importance of Gut Health Your gut microbiota, the […]
MPN Symptom Burden: Discrepancy Between Patients & Doctors
Doctors Miss the Mark on MPN Symptoms, New Study Shows by David Wallace We’ve suspected it for years, but now there’s proof: doctors aren’t fully grasping how bad MPN symptoms really are for patients. I just read this eye-opening study from a German research group that tracked almost 4,000 MPN patients, and the disconnect between […]
UVA Researcher Receives $2.4M for MPN Progression Study
by David Wallace The National Institutes of Health (NIH) has awarded a $2.4 million grant to Dr. Golam Mohi, a professor in the Department of Biochemistry and Molecular Genetics at the University of Virginia, to advance understanding of a group of blood cancers known as myeloproliferative neoplasms (MPNs). The research project, titled “Molecular Basis for […]
PV Remission to Recovery: Overcoming Life’s Challenges
by David Wallace A New Year, a New Perspective As 2025 begins, I’ve been reflecting on the unpredictable journey of aging—a path that’s less about smooth sailing and more about navigating challenges. After four years living in remission from polycythemia vera (PV), I’ve come to understand that maintaining good health requires resilience to overcome challenges […]
A Promising Drug for Breast Cancer Shows Potential to Treat MPN Blood Cancers
by David Wallace Researchers have discovered a new therapeutic avenue targeting a protein called RSK1 (ribosomal protein S6 kinase A1), which could revolutionize treatment for blood cancers such as Myeloproliferative Neoplasms (MPN) and secondary Acute Myeloid Leukemia (sAML). This protein plays a crucial role in driving cancer progression and inflammation. The Drug’s Mechanism The investigational […]
How Does Polycythemia Vera Differ from Polycythemia?
by David Wallace Polycythemia: A Comprehensive Overview Polycythemia is defined as having an abnormally high number of red blood cells in the blood—derived from the Latin “poly” (many), “cyte” (cell), and “hemo” (blood). This general term encompasses various conditions leading to this hematological abnormality. Polycythemia Vera (PV) fits under this umbrella but has its own […]
New Scoring Model Improves Prediction of Outcomes in Essential Thrombocythemia
by David Wallace Summary: Researchers have developed a new Essential Thrombocythemia scoring system called the “triple A” (AAA) model to predict outcomes in patients with essential thrombocythemia (ET), a type of blood cancer. This model uses three simple factors: age, absolute neutrophil count, and absolute lymphocyte count to categorize patients into different risk groups. The […]
- 1
- 2
- 3
- …
- 21
- Next Page »
